Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy undergraduate students aged 16 to 25 years~* Sign the informed consent~* Provide ID~Exclusion Criteria:~* Axillary temperature \> 37.0 centigrade at the time of dosing~* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine~* Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain~* Autoimmune disease or immunodeficiency~* Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)~* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~* History or family history of convulsions, epilepsy, brain disease and psychiatric~* History of any blood products within 3 months~* Administration of any other investigational research agents within 30 days~* Administration of any live attenuated vaccine within 30 days~* Administration of subunit or inactivated vaccines within 14 days~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent~* anti-HBsAg positive~* anti-HAV positive~* Pregnancy test result is positive

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Inactivated HAV vaccine (Type: EXPERIMENTAL): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
- Live attenuated HAV vaccine (Type: ACTIVE_COMPARATOR): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
- Two-dose inactivated HAV vaccine (Type: EXPERIMENTAL): Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).